Methods comprising apoptosis inhibitors for the generation of transgenic pigs

Stem Cell Clinic
Patient Application
FAQ
Contact
Locations
News
Videos
Research
Patents
3D Culture/Scaffold
Administration
Differentiation
Expansion
Extraction/Preservation
Mobilization
Type
USE
 


Stem Cell Related Patent Number US6933326

Title:Particulate acellular tissue matrix
Inventors:Griffey, Edward S.; Phillipsburg, NJ, USA
Livesey, Stephen A.; Eltham, Australia
Schiff, Charles M.; The Woodlands, TX, USA
Boerboom, Lawrence E.; The Woodlands, TX, USA
Summary:Described herein are methods of production and processing of a particulate acellular tissue matrix, and uses thereof. The invention relates to the generation of a particulate acellular tissue matrix via the cutting of sheets of dry acellular tissue matrix into strips, the cryofracturing of the dry acellular tissue matrix strips at cryogenic temperatures, the separation of the resulting particles by size at cryogenic temperatures, and the freeze-drying of the fraction of particles at the desired size to remove any moisture that may have been absorbed to give a dry particulate acellular tissue matrix. Methods of rehydration are provided, as are properties of pharmaceutically active compounds which may be combined with the rehydrated particulate material. Further described are analgesic drugs, hemostatic drugs, antibiotics and local anesthetics which may be employed to enhance the acceptance of the implanted particulate material, which may also be combined with stem cells selected from mesenchymal, epidermal, cartilage, hematopoietic and other stem cells, and combinations thereof. Therapeutic applications in the treatment of dermatological, urological and otolaryngological disorders are included.
Abstract:A method of processing an acellular tissue matrix to give a particulate acellular tissue matrix includes: cutting sheets of dry acellular tissue matrix into strips; cryofracturing the dry acellular tissue matrix strips at cryogenic temperatures; separating the resulting particles by size at cryogenic temperatures; and freeze drying the fraction of particles desired size to remove any moisture that may have been absorbed to give a dry particulate acellular tissue matrix. Rehydration of the dry particulate acellular tissue matrix may take place just prior to use. The particulate acellular tissue may be applied to a recipient site, by way of injection, spraying, layering, packing, in-casing or combinations thereof. The particulate acellular tissue may further include growth and stimulating agents selected from epidermal growth factor, fibroblast growth factor, nerve growth factor, keratinocyte growth factor, platelet derived growth factor, vasoactive intestinal peptide, stem cell factor, bone morphogetic proteins, chondrocyte growth factor and combinations thereof. Other pharmaceutically active compounds may be combined with the rehydrated particulate material including: analgesic drugs; hemostatic drugs; antibiotic drugs; local anesthetics and the like to enhance the acceptance of the implanted particulate material. The particulate material product may also be combined with stem cells selected from mesenchymal stem cells, epidermal stem cells, cartilage stem cells, hematopoietic stem cells and combinations thereof.
US Patent Website:Click Here for Full Text of Patent
Title Number:US6933326
Application Number:US1999000762174
Date Filed:18/06/1999
Date Published:23/08/2005
Assignee:LifeCell Coporation, The Woodlands, TX, USA


 
Copyright © 2007 The Institute for Cellular Medicine  6/18/2021